Medicines Co blood thinner cuts death risk in European ambulance trial
(Reuters) - Medicines Co's blood thinner Angiomax, when administered en route to the hospital to patients suffering a serious heart attack, significantly reduced the risk of major bleeding and death compared with commonly used heparin, according to data from a large clinical trial.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Angiomax | Bleeding | Cardiology | Clinical Trials | Health | Heart | Heart Attack | Hospitals